Shopping Cart 0
Cart Subtotal
USD 0

Xenetic Biosciences Inc (XBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Xenetic Biosciences Inc (Xenetic Biosciences), formerly General Sales & Leasing Inc is a clinical-stage biopharmaceutical company that discovers and develops next-generation biologic drugs and novel orphan oncology therapeutics. The company's pipeline products include Virexxa, ErepoXen, and OncoHist. Its lead product candidate ErepoXen is a polysialylated form of erythropoietin used to treat anemia in pre-dialysis patients with chronic kidney disease. Xenetic Biosciences' Virexxa and OncoHist are used for the treatment of progesterone receptor negative endometrial cancer and refractory acute myeloid leukemia. The company also provides biologic drugs and innovative orphan cancer drugs. It has its operations in the US and the UK. Xenetic Biosciences is headquartered in Lexington, Massachusetts, the US.

Xenetic Biosciences Inc (XBIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Xenetic Biosciences Acquires Rights to Virexxa from Kevelt 11

Partnerships 12

Xenetic Biosciences Enters into Agreement with Excivion 12

Licensing Agreements 13

Baxalta Enters into Licensing Agreement with Xenetic Biosciences 13

Equity Offering 14

Xenetic Biosciences Plans to Raise up to USD50 Million in Public Offering of Securities 14

Xenetic Biosciences Raises USD10 Million in Public Offering of Units 15

Xenetic Biosciences Raises USD10 Million in Private Placement of Shares 16

Xenetic Biosciences Raises USD0.3 Million in Private Placement of Shares 17

Debt Offering 18

Xenetic Biosciences Raises USD3 Million in Private Placement of 10% Notes 18

Acquisition 19

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 19

General Sales Completes Reverse Acquisition Transaction with Xenetic Biosciences 20

Xenetic Biosciences Completes Acquisition Of SymbioTec For USD 14.4 Million 21

Xenetic Biosciences Inc-Key Competitors 22

Xenetic Biosciences Inc-Key Employees 23

Xenetic Biosciences Inc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Nov 15, 2017: Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update 25

Aug 15, 2017: Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update 27

May 16, 2017: Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update 29

Apr 03, 2017: Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update 30

Corporate Communications 32

Oct 31, 2017: Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer 32

Aug 14, 2017: Xenetic Biosciences Announces Appointment of Three Directors to the Board 33

Apr 04, 2017: Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer 34

Jan 04, 2017: Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer 35

Product News 36

Apr 20, 2017: Xenetic Biosciences' PolyXen Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston 36

Other Significant Developments 37

Mar 27, 2017: Xenetic Biosciences Provides Update on Patent Portfolio Development 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Xenetic Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Xenetic Biosciences Acquires Rights to Virexxa from Kevelt 11

Xenetic Biosciences Enters into Agreement with Excivion 12

Baxalta Enters into Licensing Agreement with Xenetic Biosciences 13

Xenetic Biosciences Plans to Raise up to USD50 Million in Public Offering of Securities 14

Xenetic Biosciences Raises USD10 Million in Public Offering of Units 15

Xenetic Biosciences Raises USD10 Million in Private Placement of Shares 16

Xenetic Biosciences Raises USD0.3 Million in Private Placement of Shares 17

Xenetic Biosciences Raises USD3 Million in Private Placement of 10% Notes 18

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 19

General Sales Completes Reverse Acquisition Transaction with Xenetic Biosciences 20

Xenetic Biosciences Completes Acquisition Of SymbioTec For USD 14.4 Million 21

Xenetic Biosciences Inc, Key Competitors 22

Xenetic Biosciences Inc, Key Employees 23

Xenetic Biosciences Inc, Subsidiaries 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Xenetic Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.